- SID Score
- 5.5/10
- Fair value
- $30.58
- Generated
- Nov 2, 2026
- Model
- claude-haiku-4-5-20251001
Roche Holding AG trades at $61.27 with a market capitalization of $318.7 billion, reflecting its position as a major global pharmaceutical company. The stock carries a significantly elevated P/E ratio of 44.08, suggesting the market is pricing in substantial future growth expectations relative to current earnings. With an analyst consensus of "Hold" and a fair value estimate of $30.58 implying 50.1% downside, the valuation presents a notable disconnect between current price and intrinsic value assessments. The SID Score of 5.5/10 indicates moderate investment quality with mixed fundamental characteristics.
Recent earnings performance has been generally positive, with Roche beating consensus estimates in three of the last four quarters, most notably delivering $11.10 EPS versus expectations of $10.94 in June 2025 and $10.23 versus $9.34 in June 2024. The P/E ratio of 44.08 is substantially elevated compared to healthcare sector averages, raising concerns about growth sustainability and valuation compression risk. Factor grades reveal significant weaknesses, particularly the "F" grade in Value and only "C" grades across Growth, Profitability, Momentum, and Dividends, indicating the stock is not attractively priced from a value perspective. The minimal dividend yield of 0.03% suggests Roche prioritizes capital allocation toward research, development, and potential share buybacks rather than income distribution.
Technical analysis is severely limited as moving average data is unavailable, preventing assessment of trend momentum and support/resistance levels. The lack of RSI(14) data further restricts momentum and overbought/oversold condition analysis. Without these standard technical indicators, investors cannot utilize price trend analysis, moving average convergence, or volatility metrics to inform entry/exit timing decisions. This data limitation suggests reliance on fundamental and sentiment-based analysis becomes more critical for investment decision-making.
Analyst & Insider Sentiment
The analyst consensus rating of "Hold" with an average price target of $57.00 represents approximately 7% downside from current price levels, suggesting limited upside potential in the near term. Recent insider activity shows minimal trading volume with zero-share transactions reported across multiple dates, providing little insight into management confidence or conviction levels. The absence of significant insider buying activity is concerning, as it fails to demonstrate that company leadership views current valuations as attractive. Neutral news sentiment further supports a cautious stance, with no catalysts apparent to justify the elevated valuation multiples.
The primary risk stems from valuation compression, as the 44.08 P/E ratio leaves limited margin of safety and high sensitivity to earnings disappointments or growth slowdowns. Regulatory and competitive pressures in pharmaceuticals, combined with potential patent expirations on key drugs, could materially impact future earnings growth and justify the fair value discount of 50.1%. Currency fluctuation risks exist given Roche's global operations, with earnings translated from multiple foreign currencies. The disconnect between the current price and fair value estimate suggests significant downside risk if market sentiment shifts or earnings fail to sustain consensus expectations.
Roche presents a fundamentally challenged investment case at current prices, with a "Hold" recommendation appearing appropriately cautious given the valuation premium relative to intrinsic value assessments. While the company demonstrates consistent earnings beat capability and maintains its position as a pharmaceutical industry leader, the 44.08 P/E multiple offers insufficient margin of safety for new investors. The fair value estimate of $30.58 and analyst price target of $57.00 both suggest downside risk, particularly if growth rates decelerate or market conditions deteriorate. Risk-averse investors should await either significant price correction to $50-55 levels or clearer evidence of transformative growth drivers before establishing positions, while existing shareholders may consider taking profits given limited upside at current valuations.
